COCRYSTAL PHARMA, INC. Debt Conversion, Converted Instrument, Amount
COCRYSTAL PHARMA, INC. (COCP) reported Debt Conversion, Converted Instrument, Amount of $5.40 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2014-03-31
- COCRYSTAL PHARMA, INC. debt conversion, converted instrument, amount for fiscal 2013 was $5.40M.
| Period end | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|
| 2013-12-31 | $5.40M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |